Navigation Links
Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
Date:10/27/2008

Phase 3 and Open Label Extension Results Support Efficacy and Safety of Pegloticase

EAST BRUNSWICK, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that data from its pegloticase pivotal clinical studies in treatment-failure gout (TFG) patients was presented at scientific sessions during the annual meeting of the American College of Rheumatology (ACR). Four presentations focused on results from the pegloticase double blind placebo controlled Phase 3 pivotal studies. Data from the interim results of the uncontrolled open label extension (OLE) study were included as well. The data presented at the sessions extended the positive clinical results previously reported by the Company and further demonstrated the safety and efficacy of this novel biological drug in treatment for up to one year or longer. The presentations included results and analyses in three areas not previously discussed that included the effect of pegloticase on gout tophi, gout flares, and the immune response to pegloticase in patients with long-term treatment.

The results from the OLE study were consistent with findings from the Phase 3 studies, both of which met the primary endpoint relating to the normalization of plasma uric acid, for pegloticase 8 mg intravenous infusion every 2 weeks or every 4 weeks. A substantial subset of patients who completed the Phase 3 clinical trials and enrolled in the OLE continued to show improvements in the resolution of their signs and symptoms of treatment-failure gout with continuing pegloticase treatment, extending the positive clinical results seen in Phase 3. The two clinical efficacy endpoints of most interest, gout flares and gout tophi, showed an increasing proporti
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
2. Intensive Lifestyle Intervention Program for Overweight or Obese Patients with Nonalcoholic Steatohepatitis Reduces Weight and Improves Overall Liver Health
3. UKs NICE Recommends Spinal Cord Stimulation for Patients with Chronic Neuropathic Pain
4. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
5. AdvanDxs PNA FISH(TM) Test Shown to Reduce Mortality by 42% for Patients With Hospital-Acquired Enterococcus faecium Bloodstream Infections
6. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
7. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
8. Novel Mass Spectrometry-based Assay Reveals Degradation and Low Levels of Bioactive B-type Natriuretic Peptide (BNP) in Patients with Heart Failure
9. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
10. DaVita Treats Thousands of Dialysis Patients in Wake of Hurricane Ike
11. Fujitsu PalmSecure and HT Systems PatientSecure Selected by BayCare Health System to Protect Patient Confidentiality and Prevent Medical Identity Theft
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014 Ontotext S4 , ... Ontotext . Now the same enterprise hardened ... structured and unstructured data is available to start-ups and ... enterprise technology. Organizations that do not have resources to ... can use S4 since there is no need for ...
(Date:8/20/2014)... to biotechnology firms has revealed early bottlenecks on ... the researchers suggest that better communication of basic ... to faster commercialization down the road. , Biopharmaceutical ... university laboratories and licensed to biotechnology firms. Bottlenecks ... a high failure rate. But a new study ...
(Date:8/20/2014)... Group finds that the vascular access device market in ... and China (BRIC) was valued ... of the United States market that year. ... as a result of strong economic expansion, improving access to healthcare ... Resources Group,s coverage of the BRIC vascular access device market: ...
(Date:8/20/2014)... the health of your heart, researchers have discovered. , ... standard TENS machine like those designed to relieve labour ... small raised flap at the front of the ear ... stimulation changed the influence of the nervous system on ... drive failing hearts too hard. , Professor Jim Deuchars, ...
Breaking Biology Technology:Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3'Tickling' your ear could be good for your heart 2
... remains inexpensive to use and difficult to regulate, e-mail ... marketers proceed cautiously and ethically to safeguard their reputation. ... of all electronic mail on the Internet is unsolicited ... , said that much of the increased spam comes ...
... BioDiesel, LLC has received construction and operating permits from ... eight million gallon fuel production facility in Cashton. , ,The ... wholly owned subsidiary of BEST BioDiesel, a Madison-based fuel technology ... in the Cashton Green Energy Park, the facility will be ...
... Note: This is the text of Chris Shipley's keynote speech ... Desert, Calif. , , I shouldn't be surprised ... you. You are at the very center of an exciting ... increasingly distributed, individuals themselves become increasingly powerful. , ,Quite honestly, ...
Cached Biology Technology:Viewing the Internet as a free-for-all can be costly 2Viewing the Internet as a free-for-all can be costly 3Age of empowered individuals: People power behind robust computing 2Age of empowered individuals: People power behind robust computing 3Age of empowered individuals: People power behind robust computing 4Age of empowered individuals: People power behind robust computing 5
(Date:8/20/2014)... Issue Serious allergic reactions to food ... for some children.    What you should know ... allergies and this number may be increasing, especially among children. ... have food allergies.  The symptoms of allergic ... breathing difficulties and loss of consciousness. Symptoms can also develop ...
(Date:8/20/2014)... SILICON VALLEY, Calif., August 19, 2014 -- Bay Area ... to diagnose and simple to cure, applauds new research ... review journal Ticks and Tick-borne Diseases . ... in Northwest California are active throughout the year, making ... conducted by researchers at California Department of Public Health ...
(Date:8/20/2014)... seawater signals a relaxing trip to the shore. But ... comes with an environmental hitch. When certain sunblock ingredients ... become toxic to some of the ocean,s tiniest inhabitants, ... animals. Their study appears in the ACS journal ... David Snchez-Quiles point out that other than staying indoors, ...
Breaking Biology News(10 mins):Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3
... March 10, 2010 - The C.S. Mott Center for Human ... Wayne State University School of Medicine, in collaboration with the ... and the Institute for Environmental Health Sciences, installed a Genomatix ... year at their labs in Detroit, MI in order to ...
... Patients with irritable bowel syndrome are at no greater ... diseases than healthy people undergoing colonoscopies, according to new ... . "Patients and doctors get nervous about the ... Chey, M.D., professor of Internal Medicine at the University ...
... papaya is gaining credibility in Western medicine for anticancer ... University of Florida researcher Nam Dang, M.D., Ph.D., and ... against a broad range of lab-grown tumors, including cancers ... researchers used an extract made from dried papaya leaves, ...
Cached Biology News:Genomatix gives a hand in the analysis of Wayne State's sequencing projects 2Patients with Irritable Bowel Syndrome not more likely to develop polyps, colon cancer 2Papaya extract thwarts growth of cancer cells in lab tests 2